Prevalence of Cryptococcal Antigenemia and Cost-Effectiveness of a Cryptococcal Antigen Screening Program - Vietnam

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Smith, Rachel M ^a,b   Nguyen, Tuan Anh ^c   Ha, Hoang Thi Thanh ^c   Thang, Pham Hong ^c   Thuy, Cao ^d   Xuan Lien, Truong ^e   Bui, Hien T ^a   Le, Thai Hung ^a   Struminger, Bruce ^a   McConnell, Michelle S ^a   Fanfair, Robyn Neblett ^b   Park, Benjamin J ^b   Harris, Julie R ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c National Institute for Hygiene and Epidemiology   (Viet Nam)

^d National Hospital of Tropical Diseases   (Viet Nam)

^e PASTEUR INSTITUTE   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FUNGUS ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CRYPTOCOCCAL MENINGITIS; DRUG COST; HEALTH CARE COST; HUMAN; PRACTICE GUIDELINE; PREVALENCE; SCREENING TEST; SENSITIVITY ANALYSIS; SYMPTOMATOLOGY; VIET NAM; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BLOOD; COST BENEFIT ANALYSIS; CRYPTOCOCCUS; ECONOMICS; IMMUNOLOGY; MASS SCREENING; MENINGITIS, CRYPTOCOCCAL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIGENS, FUNGAL; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; CRYPTOCOCCUS; HUMANS; MASS SCREENING; MENINGITIS, CRYPTOCOCCAL; PREVALENCE; VIETNAM;

EID: 84876583125     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062213     Document Type: Article

References (47)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530.
2. Louie JK, Chi NH, Thao le TT, Quang VM, Campbell J, et al. (2004) Opportunistic infections in hospitalized HIV-infected adults in Ho Chi Minh City, Vietnam: a cross-sectional study. Int J STD AIDS 15: 758-761.
3. Senya C, Mehta A, Harwell JI, Pugatch D, Flanigan T, et al. (2003) Spectrum of opportunistic infections in hospitalized HIV-infected patients in Phnom Penh, Cambodia. Int J STD AIDS 14: 411-416.
4. Kong BN, Harwell JI, Suos P, Lynen L, Mohiuddin S, et al. (2007) Opportunistic infections and HIV clinical disease stage among patients presenting for care in Phnom Penh, Cambodia. Southeast Asian J Trop Med Public Health 38: 62-68.
5. Espie E, Pinoges L, Balkan S, Chanchhaya N, Molfino L, et al. (2010) Cryptococcal meningitis in HIV-infected patients: a longitudinal study in Cambodia. Trop Med Int Health 15: 1375-1381.
6. Chhin S, Rozycki G, Pugatch D, Harwell JI, (2004) Aetiology of meningitis in HIV-infected patients in a referral hospital in Phnom Penh, Cambodia. Int J STD AIDS 15: 48-50.
7. Lortholary O, Poizat G, Zeller V, Neuville S, Boibieux A, et al. (2006) Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 20: 2183-2191.
8. French N, Gray K, Watera C, Nakiyingi J, Lugada E, et al. (2002) Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 16: 1031-1038.
9. Pongsai P, Atamasirikul K, Sungkanuparph S, (2010) The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts. J Infect 60: 474-477.
10. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, et al. (2007) Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 12: 929-935.
11. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, et al. (2009) Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 48: 856-862.
12. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, et al. (2010) Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis 51: 448-455.
13. Organization WH (2011) Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Geneva, Switzerland: World Health Organization.
14. Lindsley MD, Mekha N, Baggett HC, Surinthong Y, Autthateinchai R, et al. (2011) Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis 53: 321-325.
15. Rajasingham R, Meya DB, Boulware DR, (2012) Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 59: e85-91.
16. Micol R, Tajahmady A, Lortholary O, Balkan S, Quillet C, et al. (2010) Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia. PLoS One 5: e13856.
17. Micol R, Lortholary O, Sar B, Laureillard D, Ngeth C, et al. (2007) Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 45: 555-559.
18. Vietnam MoH (2009) Vietnam HIV/AIDS Estimates and Projections 2007-2012. In: Control VAoHA, editor. Hanoi: Family Health International.
19. do Cuong D, Thorson A, Sonnerborg A, Hoa NP, Chuc NT, et al. (2012) Survival and causes of death among HIV-infected patients starting antiretroviral therapy in north-eastern Vietnam. Scand J Infect Dis 44: 201-208.
20. Klotz SA, Nguyen HC, Van Pham T, Nguyen LT, Ngo DT, et al. (2007) Clinical features of HIV/AIDS patients presenting to an inner city clinic in Ho Chi Minh City, Vietnam. Int J STD AIDS 18: 482-485.
21. Parekh BS, Kennedy MS, Dobbs T, Pau CP, Byers R, et al. (2002) Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses 18: 295-307.
22. Shah N, Le L, Ha HT, Quang PD, Cuc CT,et al. Evaluating the accuracy of the BED capture enzyme immunoassay and rIDRM limiting antigen avidity assay in detecting long-term infection in a sample of known chronic HIV infections in Vietnam; 2011; Boston.
23. Organization WH (2001) Macroeconomics and health: investing in health for economic development. Report of the commission on macroeconomics and health.
24. Organization WH (2012) Table: Threshold values for intervention cost-effectiveness by Region.
25. (2009) Guidelines for HIV/AIDS diagnosis and treatment. In: Control VAoHA, editor. Hanoi: Ministry of Health.
26. Govender N, Chetty V, Roy M, Chiller T, Oladoyinbo S, et al. (2012) Phased Implementation of Screening for Cryptococcal Disease in South Africa. South African Medical Journal 102: 914-917.
27. Rajasingham R, Boulware DR (2012) Reconsidering Cryptococcal Antigen Screening in the U.S. among persons with CD4<100 cells/mcL. Clin Infect Dis.
28. Tassie JM, Pepper L, Fogg C, Biraro S, Mayanja B, et al. (2003) Systematic screening of cryptococcal antigenemia in HIV-positive adults in Uganda. J Acquir Immune Defic Syndr 33: 411-412.
29. Huynh TX, Nguyen HC, Vo MQ, Odermatt-Biays S, Degremont A, et al. (2003) [Cryptococosis and HIV/AIDS: a review of 21 cases reported in the Tropical Diseases Centre, Ho Chi Minh City (Vietnam)]. Sante 13: 225-229.
30. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, et al. (2011) Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 155: 209-216.
31. Fang CT, Chang YY, Hsu HM, Twu SJ, Chen KT, et al. (2007) Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM 100: 97-105.
32. Pfizer I (2011) Pfizer Investments in Health.
33. Kendi C, Penner J, Otieno B, Odhiambo N, Bukusi E,et al. Routine cryptococcal screening and treatment in Kenya: outcomes after six months of follow up; 2011; Rome, Italy.
34. Le H, Nguyen HD, Cao TT, West GR, Kamb ML, et al. (2001) Surveillance for Clinical Manifestation of HIV/AIDS Disease and Opportunistic Infection (OIs) in Hanoi, Vietnam; 2001; Melbourne.
35. Organization WH (2008) Essential prevention and care interventions for adults and adolescents living with HIV in resource-limited settings. Geneva, Switzerland.
36. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE, (2002) A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 34: 277-284.
37. Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, Mootsikapun P, Boonyaprawit P, (2004) A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Med 5: 140-143.
38. McKinsey DS, Wheat LJ, Cloud GA, Pierce M, Black JR, et al. (1999) Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 28: 1049-1056.
39. Smith DE, Bell J, Johnson M, Youle M, Gazzard B, et al. (2001) A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection. HIV Med 2: 78-83.
40. Chang LW, Phipps WT, Kennedy GE, Rutherford GW (2005) Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev: CD004773.
41. Osazuwa F, Dirisu JO, Okuonghae PE, Ugbebor O, (2012) Screening for cryptococcal antigenemia in anti-retroviral naive AIDS patients in benin city, Nigeria. Oman Med J 27: 228-231.
42. Roy M, Chiller T, (2011) Preventing deaths from cryptococcal meningitis: from bench to bedside. Expert Rev Anti Infect Ther 9: 715-717.
43. Bank TW (2012) GDP per Capita (Current US$).
44. Abimbola TO, Marston BJ, (2012) The cost-effectiveness of cotrimoxazole in people with advanced HIV infection initiating antiretroviral therapy in sub-Saharan Africa. J Acquir Immune Defic Syndr 60: e8-e14.
45. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, et al. (2006) Cost-effectiveness of HIV treatment in resource-poor settings-the case of Cote d'Ivoire. N Engl J Med 355: 1141-1153.
46. Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, et al. (2006) When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther 11: 63-72.
47. Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, et al. (2007) Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 21Suppl 4: S117-128.